Healius (ASX:HLS) has completed its operating & strategic review culminating in the sale of its Lumus Imaging unit for AU$965 million, according to a Thursday Australian bourse filing.
The sale to Affinity Equity Partners is expected to complete on May 1 and its proceeds will be used to pay shareholders a special dividend of AU$0.41 per share.
After the Lumus sale, the company said it would save AU$15 million to AU$20 million in costs by cutting unallocated corporate costs and pathology expenses.
The company's shares were up 13% in recent Thursday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。